Merck Serono Focuses On China For Expansion
This article was originally published in PharmAsia News
Executive Summary
Merck Group's Chairman of the Executive Board Karl-Ludwig Kley declared that the company will expand its investment in China and other Asian countries in the near future. China has been one of Merck's top 10 markets for antitumor drug Erbitux (cetuximab), with sales growing over 70 percent this year. However, the company thinks there is still potential for greater performance. Merck's pharmaceutical business in 2007 hit €4.88 billion, of which Serono's prescription drugs contributed €4.46 billion. Serono concentrates on oncology, neurodegenerative disease, autoimmune and inflammatory disease, as well as infertility and endocrine disease. Merck hopes that Serono will become one of the top 15 pharmaceutical companies in China before 2012. (Click here for more - Chinese Language)
You may also be interested in...
China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’
China’s public payer perceives innovative drugs in a different way from that of the country’s top drug regulator, a former senior healthcare security official with knowledge of the matter reveals. The posture has unnerved pharma companies, which have been hit by sharp price discounts.
Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116
As Merck’s 21-valent vaccine approaches its 17 June user fee goal, the US CDC’s vaccine committee is looking at new adult age-based recommendations and bracing for a full pipeline led by GSK’s 24-valent candidate.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.